Bailard, Inc. Glycomimetics Inc Transaction History
Bailard, Inc.
- $3.8 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding GLYC
# of Institutions
35Shares Held
17.8MCall Options Held
0Put Options Held
0-
Bvf Inc San Francisco, CA9.54MShares$2.96 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.67MShares$827,7640.0% of portfolio
-
Siren, L.L.C. New York, NY1.97MShares$609,1850.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny781KShares$242,1410.0% of portfolio
-
Black Rock Inc. New York, NY723KShares$224,1870.0% of portfolio
About GLYCOMIMETICS INC
- Ticker GLYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,423,900
- Market Cap $16.3M
- Description
- GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...